USPTOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die US-Marke EPTEST wurde als Wortmarke am 25.03.2003 beim Amerikanischen Patent- und Markenamt angemeldet. Der aktuelle Status der Marke ist "ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE".
Markeninhaber
c/o Miller & Canfield,1450 Broadway,41st Floor
10018 New York
US
10018 New York
US
Markenvertreter
Waren und Dienstleistungen
5
Pharmaceutical preparations; antibody preparations; chemical preparations for use in performing polymerase chain reactions (PCR); monoclonal antibodies; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to antigens; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to vaccines; diagnostic preparations and reagents for sale in kit form; biological preparations; biological cultures; cell cultures; cell lines; chemical preparations; cultures of micro organisms; diagnostic preparations; enzymes; genes; DNA; RNA; peptides; polypeptides; proteins; recombinant antibodies; vaccines; including all of the above aforesaid goods for the treatment of amyloidosis, Alzheimer's Disease, Down Syndrome and Mild Cognitive Impairment (MCI); Pharmaceutical preparations; antibody preparations; chemical preparations for use in performing polymerase chain reactions (PCR); monoclonal antibodies; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to antigens; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to vaccines; diagnostic preparations and reagents for sale in kit form; biological preparations; biological cultures; cell cultures; cell lines; chemical preparations; cultures of micro organisms; diagnostic preparations; enzymes; genes; DNA; RNA; peptides; polypeptides; proteins; recombinant antibodies; vaccines; including all of the above aforesaid goods for the treatment of amyloidosis, Alzheimer's Disease, Down Syndrome and Mild Cognitive Impairment (MCI)
10
Diagnostic test kits; diagnostic test kits for use in polymerase chain reactions (PCR) ; diagnostic test kits and apparatus for determination of an individual's HLA haplotype reaction with vaccines; all the aforesaid for determination of an individual's HLA haplotype reaction with vaccines against Alzheimer's Disease, MCI, amyloidosis and Down Syndrome.; Diagnostic test kits; diagnostic test kits for use in polymerase chain reactions (PCR) ; diagnostic test kits and apparatus for determination of an individual's HLA haplotype reaction with vaccines; all the aforesaid for determination of an individual's HLA haplotype reaction with vaccines against Alzheimer's Disease, MCI, amyloidosis and Down Syndrome.
42
Scientific, medical and industrial research; vaccine screening; biochemical analysis, biochemical research; diagnosis of predisposition to Alzheimer's Disease, Mild Cognitive Impairment (MCI); amyloidosis and Down Syndrome; disease management; drug design; healthcare; prophylaxis and treatment of medical disorders; prophylaxis, vaccination, vaccine screening, and treatment of Alzheimer's Disease, Down Syndrome, Mild Cognitive Impairment (MCI) and amyloidosis.; Scientific, medical and industrial research; vaccine screening; biochemical analysis, biochemical research; diagnosis of predisposition to Alzheimer's Disease, Mild Cognitive Impairment (MCI); amyloidosis and Down Syndrome; disease management; drug design; healthcare; prophylaxis and treatment of medical disorders; prophylaxis, vaccination, vaccine screening, and treatment of Alzheimer's Disease, Down Syndrome, Mild Cognitive Impairment (MCI) and amyloidosis.
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
ID: 1378229836